Natalia Misciattelli
Chief Executive Officer chez AAVantgarde Bio Srl
Profil
Natalia Misciattelli is currently the Chief Executive Officer at AAVantgarde Bio Srl and an Advisor at Atlas Venture Advisors, Inc. She was previously a Partner at PA Consulting Group Ltd.
from 2011 to 2017, Head of Corporate Development & Strategy at General Electric Healthcare Technologies, Inc., Senior Vice President-Strategy at Freeline Therapeutics Holdings Plc from 2017 to 2020, and Chief Business Officer at Novalgen Ltd.
She received her undergraduate and doctorate degrees from the University of Bangor.
Postes actifs de Natalia Misciattelli
| Sociétés | Poste | Début |
|---|---|---|
AAVantgarde Bio Srl
 AAVantgarde Bio Srl Miscellaneous Commercial ServicesCommercial Services AAVantgarde Bio Srl is a clinical stage biotechnology start-up based in Milan, Italy. The Italian company has developed proprietary adeno-associated viral (AAV) vector platforms that allow for the delivery of large genes for inherited retinal disorders. Co-founded by Professor Alberto Auricchio and originating from the research activities carried out at TIGEM (Telethon Institute of Genetics and Medicine), AAVantgarde's platforms are focused on broadening the application of AAV-based therapies by addressing the limitations of single AAV therapies cargo capacity. Natalia Misciattelli has been the CEO of the company since 2022. | Chief Executive Officer | 08/09/2022 |
Atlas Venture Advisors, Inc.
 Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Consultant / Advisor | - |
Anciens postes connus de Natalia Misciattelli
| Sociétés | Poste | Fin |
|---|---|---|
| FREELINE THERAPEUTICS HOLDINGS PLC | Corporate Officer/Principal | 01/12/2020 |
PA Consulting Group Ltd.
 PA Consulting Group Ltd. Miscellaneous Commercial ServicesCommercial Services PA Consulting Group Ltd. engages in the provision of management, systems, technology consulting, and innovation services. The company was founded by Ernest Button on September 3, 2015 and is headquartered in London, the United Kingdom. | Corporate Officer/Principal | 02/09/2017 |
Novalgen Ltd.
 Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The private company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | Corporate Officer/Principal | - |
General Electric Healthcare Technologies, Inc.
 General Electric Healthcare Technologies, Inc. Medical/Nursing ServicesHealth Services General Electric Healthcare Technologies, Inc. provides transformational medical technologies and services. The company is headquartered in Houston, TX. | Corporate Officer/Principal | - |
Formation de Natalia Misciattelli
| University Of Bangor | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
PA Consulting Group Ltd.
PA Consulting Group Ltd. Miscellaneous Commercial ServicesCommercial Services PA Consulting Group Ltd. engages in the provision of management, systems, technology consulting, and innovation services. The company was founded by Ernest Button on September 3, 2015 and is headquartered in London, the United Kingdom. | Commercial Services |
Atlas Venture Advisors, Inc.
Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Finance |
General Electric Healthcare Technologies, Inc.
General Electric Healthcare Technologies, Inc. Medical/Nursing ServicesHealth Services General Electric Healthcare Technologies, Inc. provides transformational medical technologies and services. The company is headquartered in Houston, TX. | Health Services |
Freeline Therapeutics Holdings Plc
 Freeline Therapeutics Holdings Plc BiotechnologyHealth Technology Freeline Therapeutics Holdings Plc engages in the business of developing and commercializing gene therapies. It also develops gene therapies for bleeding and other debilitating disorders. The company was founded by Markus Hörer and Amit Chunilal Nathwani in 2015 and is headquartered in Stevenage, the United Kingdom. | Health Technology |
Novalgen Ltd.
Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The private company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | Health Technology |
AAVantgarde Bio Srl
AAVantgarde Bio Srl Miscellaneous Commercial ServicesCommercial Services AAVantgarde Bio Srl is a clinical stage biotechnology start-up based in Milan, Italy. The Italian company has developed proprietary adeno-associated viral (AAV) vector platforms that allow for the delivery of large genes for inherited retinal disorders. Co-founded by Professor Alberto Auricchio and originating from the research activities carried out at TIGEM (Telethon Institute of Genetics and Medicine), AAVantgarde's platforms are focused on broadening the application of AAV-based therapies by addressing the limitations of single AAV therapies cargo capacity. Natalia Misciattelli has been the CEO of the company since 2022. | Commercial Services |
